ABS 0871
Alternative Names: ABS-0871Latest Information Update: 01 Oct 2024
At a glance
- Originator Actio Biosciences
- Class Small molecules
- Mechanism of Action TRPV4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bone disorders; Charcot marie tooth disease type 2C
Most Recent Events
- 25 Sep 2024 Actio Biosciences plans a phase I clinical trial for Charcot-Marie-Tooth disease and bone disorders by year-end 2024
- 08 Aug 2024 ABS 0871 receives Orphan Drug status for Charcot-Marie-Tooth disease type-2C in USA
- 08 Aug 2024 ABS 0871 receives Rare pediatric disease designation for Charcot-Marie-Tooth disease type-2C in USA